Top

Published in:

01-04-2007 | Leading Article

Use of Pharmacodynamic Principles to Optimise Dosage Regimens for Antibacterial Agents in the Elderly

Authors: Ayman M. Noreddin, Virginia Haynes

Published in: Drugs & Aging | Issue 4/2007

Abstract

Throughout most of the world we are witnessing an ever increasing number of aged people as a percentage of the general population. In the coming years, the unique spectrum of infections presented by an elderly population, particularly those in long-term care facilities, will challenge our ability to maintain an effective battery of antibacterials. The pharmacokinetic parameters of most antibacterial agents are altered when assessed in the elderly due in part to non-pathological physiological changes. The inability to clear a drug from the body due to declining lung, kidney/bladder, gastrointestinal and circulatory efficiency can cause accumulation in the body of drugs given in standard dosages. While this may have the potential benefit of achieving therapeutic concentrations at a lower dose, there is also a heightened risk of attaining toxic drug concentrations and an increased chance of unfavourable interactions with other medications. Pharmacodynamic issues in the elderly are related to problems that arise from treating elderly patients who may have a history of previous antibacterial treatment and exposure to resistant organisms from multiple hospitalisations. Furthermore, the elderly often acquire infections in tandem with other common disease states such as diabetes mellitus and heart disease. Thus, it is essential that optimised dosage strategies be designed specifically for this population using pharmacodynamic principles that take into account the unique circumstances of the elderly. Rational and effective dosage and administration strategies based on pharmacodynamic breakpoints and detailed understanding of the pharmacokinetics of antibacterials in the elderly increase the chances of achieving complete eradication of an infection in a timely manner. In addition, this strategy helps prevent selection of drug-resistant bacteria and minimises the toxic effects of antibacterial therapy in the elderly patient.

Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985 Apr; 33(4): 278–85PubMed

Chutka DS, Evans JM, Fleming KC, et al. Drug prescribing for elderly patients. Mayo Clin Proc 1995; 70(7): 685–93PubMedCrossRef

Strausbaugh LJ, Sukumar SR, Joseph CL. Infectious disease outbreaks in nursing homes: an unappreciated hazard for frail elderly persons. Aging Infect Dis 2003; 36: 870–6CrossRef

Engelhart ST, Hanses-Derendorf L, Exner M, et al. Prospective surveillance for healthcare-associated infections in German nursing home residents. J Hosp Infect 2005; 60: 46–50PubMedCrossRef

Gavazzi G, Krause K-H. Ageing and infection. Lancet Infect Dis 2002 Nov; (2): 659–66

Wang CY, Jerng JS, Cheng KY, et al. Pandrug-resistant Pseudomonas aeruginosa among hospitalized patients: clinical features, risk factors and outcomes. Eur Soc Clin Microbiol Infect Dis 2006; 12: 63–8CrossRef

Rosenthal VD, Maki DG, Salomao R, et al. Device-associated nosocomial infections in 55 intensive care units of 8 developing countries. Ann Intern Med 2006, 92

Curtin J, Cormican M, Fleming G, et al. Linezolid compared with eperezolid, vancomycin, and gentamicin in an in vitro model of antimicrobial lock therapy for Staphylococcus epidermidis central venous catheter-related biofilm infections. Antimicrob Agents Chemother 2003 Oct; 47(10): 3145–8PubMedCrossRef

Edmiston CE Jr, Goheen MP, Seabrook GR, et al. Impact of selective antimicrobial agents on staphylococcal adherence to biomedical devices. Am J Surg 2006 Sep; 192(3): 344–54PubMedCrossRef

10.

Greene CM, Kyaw MH, Ray SM, et al. Preventability of invasive pneumococcal disease and assessment of current polysaccharide vaccine recommendations for adults: United States, 2001–2003. Clin Infect Dis 2006; 43: 141–50PubMedCrossRef

11.

McBean AM, Jung K, Hebert PL. Decreasing invasive pneumococcal disease in the elderly: a state level analysis. Vaccine 2006; 24: 5609–14PubMedCrossRef

12.

Kyaw MH, Lynfield R, Schaffner W, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug resistant Streptococcus pneumoniae. N Engl J Med 2006; 354(14): 1455–64PubMedCrossRef

13.

Stalam M, Kaye D. Antibiotic agents in the elderly. Infect Dis Clin North Am 2004; 18: 533–49PubMedCrossRef

14.

O’Donnell JA, Hofmann MT. How to manage nursing home patients with or without chronic catheterization. Infect Dis 2002; 57(5): 45–8

15.

Ferrara AM, Fietta AM. New developments in antibacterial choice for lower respiratory tract infections in elderly patients. Drugs Aging 2004; 21(3): 167–86PubMedCrossRef

16.

Nerella S, Meyer KC. Drug treatment of pneumococcal pneumonia in the elderly. Therapy Pract 2004; 21(13): 851–64

17.

Flamminger A, Maibach H. Drug dosage in the elderly: dermatologic drugs. Drugs Aging 2006; 23(3): 203–15CrossRef

18.

Wright RM, Warpula RW. Geriatric pharmacology: safer prescribing for the elderly patient. J Am Podiatr Med Assoc 2004; 94(2): 90–7PubMed

19.

Noreddin AM, Marras TK, Sanders K, et al. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500mg, 750mg and 1000mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP). Int J Antimicrob Agents 2004; 24: 479–84PubMedCrossRef

20.

Noreddin AM, Hoban DJ, Zhanel GG. Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalized patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae. Int J Antimicrob Agents 2005; 26: 120–5PubMedCrossRef

21.

Schmucker DL. Liver function and phase I drug metabolism in the elderly. Drugs Aging 2001; 18(11): 837–51PubMedCrossRef

22.

Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients. Clin Pharmacokinet 2005; 44(10): 1009–34PubMedCrossRef

23.

Wyatt CM, Kim MC, Winston JA. Therapy insight: how changes in renal function with increasing age affect cardiovascular drug prescribing. Nat Clin Pract 2005; 3(2): 102–9

24.

Trotman RL, Williamson JC, Shoemaker DM, et al. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 2005; 51: 1159–66CrossRef

25.

Zhanel GG, Noreddin AM. Pharmacokinetics and pharmacodynamics (PK/PD) of quinolones: maximizing bacterial eradication and preventing resistance. Res Adv Antimicrob Agents Chem 2004; 4: 39–67

26.

Mouton JW, Dudley MN, Cars O, et al. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chem 2005; 55: 601–7CrossRef

27.

Craig WA, Bhavnani SM, Ambrose PG. The inoculum effect: fact or artifact? Diagn Microbiol Infect Dis 2004; 50: 229–30PubMedCrossRef

28.

Noreddin AM, Haynes VL, Zhanel GG. Pharmacokinetics and pharmacodynamics of the new quinolones. J Pharm Pract 2005; 18(6): 1–12CrossRef

29.

Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials [see comments]. JAMA 1998; 279(2): 125–9PubMedCrossRef

30.

Tran JQ, Ballow CH, Forrest A, et al. Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables. J Antimicrob Chem 2000; 45: 9–17CrossRef

31.

MacGowan AP, Bowker KE, Wootton M, et al. Activity of moxifloxacin, administered once a day, against Streptococcus pneumoniae in an in vitro pharmacodynamic model of infection. Antimicrob Agents Chem 1999; 43(7): 1560–4

32.

Hershberger E, Rybak MJ. Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciproflox-acin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model. Antimicrob Agents Chem 2000; 44(3): 598–601CrossRef

33.

Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chem 1998; 42(3): 521–7

34.

Lacy MK, Lu W, Xu X, et al. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chem 1999; 43(3): 672–7

35.

Park-Wylie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006; 354: 1352–61CrossRef

36.

Park-Wyllie L, Shah BR, Juurlink DN. Correspondence. N Engl J Med 2006; 354: 2725–6CrossRef

37.

Ambrose PG, Bhavnani SM, Cirincione B, et al. Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction. J Antimicrob Chem 2003; 52: 435–40CrossRef

38.

Yamada C, Nagashima K, Takahashi A, et al. Gatifloxacin acutely stimulates insulin secretion and chronically suppresses insulin biosynthesis. Eur J Pharmacol 2006 Dec 28; 553(1–3): 67–72PubMedCrossRef

39.

Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 1073–81PubMedCrossRef

40.

Lee SY, Kuti J, Nicolau D. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg Infect 2005; 6(3): 286–95CrossRef

41.

Itani KMF, Weigelt J, Li JZ, et al. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 2005; 26: 442–8PubMedCrossRef

42.

Niederman M. Principles of appropriate antibiotic use. Int J Antimicrob Agents 2005; 26Suppl. 3: S170–5PubMedCrossRef

43.

DeRyke CA, Lee SY, Kuti JL, et al. Optimizing dosing strategies of antibacterials utilizing pharmacodynamic principles: impact on the development of resistance. Drugs 2006; 66(1): 1–14PubMedCrossRef

44.

Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987 Jan; 155(1): 93–9PubMedCrossRef

45.

Begg EJ. Individualized drug and dose: the clinical pharmacologist’s calling or curse? Exp Pharmacol Physiol 2005; 32: 975–8CrossRef

46.

Kirkpatrick CMJ, Begg EJ. Aminoglycoside dosage regimens after therapeutic drug monitoring. Clin Pharmacokinet 2002; 41(10): 791–2PubMedCrossRef

47.

Hutschala D, Skhirtladze K, Zuckermann A, et al. In vivo measurement of levofloxacin penetration into lung tissue after cardiac surgery. Antimicrob Agents Chem 2005; 49(12): 5107–11CrossRef

48.

Capitano B, Mattoes HM, Shore E, et al. Steady state intrapulmonary concentrations of moxifloxacin, levofloxacin and azithromycin in older adults. Chest 2005; 125: 965–73CrossRef

49.

Xuan D, Nicolau DP, Nightingale CH. Population pharmacokinetics of gentamicin in hospitalized patients receiving once-daily dosing. Int J Antimicrob Agents 2004; 23: 291–5PubMedCrossRef

50.

Kashuba ADM, Nafziger AN, Drusano GL, et al. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chem 1999; 43(3): 623–9

51.

Paterson DL, Robson JMB, Wagener MM, et al. Risk factors for toxicity in elderly patients given aminoglycosides once daily. J Geriatr Intern Med 1998; 13: 735–9CrossRef

52.

Rybak MJ, Abate BJ, Kang L, et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chem 1999; 43(7): 1549–55

53.

Mohanty S, Kapil A, Dhawan B, et al. Bacteriological and antimicrobial susceptibility profile of soft tissue infections from Northern India. Indian J Med Sci 2004; 58(1): 10–5PubMed

54.

Kasiakou SK, Lawrence KR, Choulis N, et al. Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: a systematic review of pharmacokinetic and pharmacodynamic parameters. Drugs 2005; 65(17): 2499–511PubMedCrossRef

55.

Lau WK, Mercer D, Itani KM, et al. Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother 2006 Nov; 50(11): 3556–61PubMedCrossRef

56.

Noreddin AM, Roberts D, Nichol K, et al. Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrations. Antimicrob Agents Chem 2002; 46(12): 4029–34CrossRef

57.

Blumer JL. Evolution of a new drug formulation: the rationale for high dose, short course therapy with azithromycin. Int J Antimicrob Agents 2005; 26Suppl. 3: S143–7PubMedCrossRef

58.

Liu P, Allaudeen H, Chandra R, et al. Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen. Antimicrob Agents Chemothe 2007 Jan; 51(1): 103–9CrossRef

59.

Moussaoui R, de Borgie CAJM, van den Broek P, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomized, double blind study. BMJ 2006; 332: 1355–60PubMedCrossRef

60.

Katchman EA, Milo G, Paul M, et al. Three-day vs longer duration of antibiotic treatment for cystitis in women: systematic review and meta-analysis. Am J Med 2005; 188: 1196–207CrossRef

61.

Ong CT, Dandekar PK, Sutherland C, et al. Intrapulmonary concentrations of telithromycin: clinical implications for respiratory tract infections due to Streptococcus pneumoniae. Chemotherapy 2005; 51: 339–46PubMedCrossRef

62.

Nguyen M, Chung EP. Telithromycin: the first ketolide antimicrobial. Clin Ther 2005; 27(8): 1144–63PubMedCrossRef

63.

Greer N. Tigecycline (Tygacil): the first in the glycylcycline class of antibiotics. Proc (Baylor Univ Med Cent) 2006; 19: 155–61

64.

Stahlmann R, Lode H. Fluoroquinolones in the elderly. Drugs Aging 2004; 20(4): 289–302CrossRef

65.

Wright DH, Brown GH, Peterson ML, et al. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chem 2000; 46: 669–83CrossRef

66.

Navarro AS, Gandarillas C-I, Lerma FA, et al. Pharmacokinetics and pharmacodynamics of levofloxacin in intensive care patients. Clin Pharmacokinet 2005; 44(6): 627–35CrossRef

67.

Cappelletty DM, Zervos M. Levofloxacin use in the elderly: focus on pneumonia. Aging Health 2006; 2(3): 371–82CrossRef

68.

Jumbe N, Louie A, Leary R, et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 2003; 112: 275–85PubMed

69.

Jumbe NL, Louie A, Miller MH, et al. Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chem 2006; 50(1): 310–7CrossRef

70.

Tarn VH, Louie A, Deziel MR, et al. Bacterial population responses to drug-selective pressure: examination of garenoxacin’s effect on Pseudomonas aeruginosa. J Infect Dis 2005; 192: 420–8CrossRef

71.

Bhavani SM, Hammel JP, Jones RN, et al. Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States. Diagn Microbiol Infect Dis 2005; 51: 31–7CrossRef

72.

Owens RC Jr, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005; 41: S144–57PubMedCrossRef

73.

Morganroth J, DiMarco JP, Anzueto A, et al. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community acquired pneumonia. Chest 2005; 128: 3398–406PubMedCrossRef

74.

Tsikouris JP, Peeters MJ, Cox CD, et al. Effects of three fluoroquinolones on QT analysis after standard treatment courses. Ann Noninvasive Electrocardiol 2006; 11(1): 52–6PubMedCrossRef

75.

Waterer GW, Kessler LA, Wunderink RG. Delayed administration of antibiotics and atypical presentation in community-acquired pneumonia. Chest 2006; 130: 11–5PubMedCrossRef

76.

Carcas AJ, García-Satué JL, Zapater P, et al. Tobramycin penetration into epithelial lining fluid of patients with pneumonia. Clin Pharmacol Ther 1999; 65: 245–50PubMedCrossRef

77.

Khaliq Y, Zhanel G. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis 2003; 36: 1404–10PubMedCrossRef

78.

Shams WE, Evans ME. Guide to selection of fluoroquinolones in patients with lower respiratory tract infections. Drugs 2005; 65(7): 949PubMedCrossRef

79.

Cohen AE, Lautenbach E, Morales KH, et al. Fluoroquinolone-resistant Escherichia coli in the long-term care setting. Am J Med 2006; 119: 958–63PubMedCrossRef

80.

Stass H, Kubitza D. Profile of moxifloxacin drug interactions. Clin Infect Dis 2001; 32Suppl. 1: S47–50PubMedCrossRef

81.

Gregg CR. Drug interactions and anti-infective therapies. Am J Med 1999; 106(2): 227–37PubMedCrossRef

82.

Singer MI, Shapiro LE, Shear NH. Cytochrome P-450 3A: interactions with dermatologic therapies. J Am Acad Dermatol 1997; 37(5): 765–71PubMedCrossRef

83.

Chu SY, Wilson DS, Guay DR, et al. Clarithromycin pharmacokinetics in healthy young and elderly volunteers. J Clin Pharmacol 1992 Nov; 32(11): 1045–9PubMed

84.

Chu SY, Granneman GR, Pichotta PJ, et al. Effect of moderate or severe hepatic impairment on clarithromycin pharmacokinetics. J Clin Pharmacol 1993; 33: 480–5PubMed

85.

Hung IFN, Wu AKL, Cheng VCC, et al. Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study. Clin Infect Dis 2005; 41: 291–300PubMedCrossRef

86.

Clay KD, Hanson JS, Pope SD, et al. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med 2006; 144: 415–20PubMed

87.

Meagher AK, Ambrose PG, Grasela TH, et al. Pharmacokinetic/pharmacodynamic profile for tigecycline: a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis 2005; 52: 165–71PubMedCrossRef

88.

Bryan CS, Talwani R, Stinson S. Penicillin dosing for pneumococcal pneumonia. Chest 1997; 112: 1657–64PubMedCrossRef

89.

Zhanel GG, Johanson C, Embil JM, et al. Ertapenem: review of a new carbapenem. Expert Rev Anti Infect Ther 2005; 3(1): 23–39PubMedCrossRef

90.

Musson DG, Majumdar A, Holland S, et al. Pharmacokinetics of total and unbound ertapenem in healthy elderly subjects. Antimicrob Agents Chem 2004 Feb; 48(2): 521–4CrossRef

91.

Hellinger WC, Brewer NS. Carbapenems and monobactams: imipenem, meropenem and aztreonam. Mayo Clin Proc 1999; 74(4): 420–34PubMedCrossRef

92.

Skhirtladze K, Hutschala D, Fleck T, et al. Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery. Antimicrob Agents Chem 2006; 50(4): 1372–5CrossRef

93.

French G. Safety and tolerability of linezolid. J Antimicrob Chem 2003; 51Suppl. S2: ii45–53

94.

Brier ME, Stalker DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chem 2003 Sept; 47(9): 2775–80CrossRef

95.

Corallo C, Pauli AE. Linezolid-induced neuropathy [letter]. Med J Aust 2002; 177(6): 332PubMed

96.

Huang V, Gortney JS. Risk of serotonin syndrome with concomitant administration of linezolid and serotonin agonists. Pharmacotherapy 2006; 26(12): 1784–93PubMedCrossRef

97.

McKee EE, Ferguson M, Bentley AT, et al. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob Agents Chem 2006 Jun; 50(6): 2042–9CrossRef

98.

DeVriese AS, Van Coster R, Smet J, et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis 2006; 42: 1111–7CrossRef

99.

Panidis D, Markantonis SL, Boutzouka E, et al. Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia. Chest 2005 Aug; 128: 545–52PubMedCrossRef

100.

Joukhadar C, Stass H, Müller-Zellenberg U, et al. Penetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humans. Antimicrob Agents Chem 2003 Oct; 47(10): 3099–103CrossRef

101.

Bellman R, Kuchling G, Dehghanyar P, et al. Tissue pharmacokinetics of levofloxacin in human soft tissue infections. Br J Clin Pharmacol 2004; 57(5): 563–8CrossRef

102.

Wagenlehner FME, Kinzig-Schippers M, Tischmeyer U, et al. Pharmacokinetics of ciprofloxacin XR (1000mg) versus levofloxacin (500mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose. Antimicrob Agents 2006; 27: 7–14CrossRef

103.

Patel KB, Xuan D, Tessier PR, et al. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob Agents Chem 1996 Oct; 40(10): 2375–9

104.

Kuehnel TS, Schurr C, Lotter K, et al. Penetration of telithromycin into the nasal mucosa and ethmoid bone of patients undergoing rhinosurgery for chronic sinusitis. J Antimicrob Chem 2005; 55: 591–4CrossRef

105.

Zhanel GG, Johanson C, Hisanaga T, et al. Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations. J Antimicrob Chem 2004; 54: 1072–7CrossRef

106.

Conte JE Jr, Golden JA, Kelly MG, et al. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Antimicrob Agents 2005; 25: 523–9CrossRef

107.

Wise R, Honeybourne D. Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract [published erratum appears in Eur Respir J 1999 Nov; 14 (5): 1239]. Eur Respir J 1999 Jul; 14(1): 221–9PubMedCrossRef

108.

Tomaselli F, Dittrich P, Maier A, et al. Penetration of piperacillin and tazobactam into pneumonic human lung tissue measured by in vivo microdialysis. Br J Clin Pharmacol 2003; 55: 620–4PubMedCrossRef

109.

Legat FJ, Krause R, Zenahlik P, et al. Penetration of piperacillin and tazobactam into inflamed soft tissue of patients with diabetic foot infection. Antimicrob Agents Chem 2005 Oct; 49(10): 4368–71CrossRef

110.

Boselli E, Breilh D, Cannesson M, et al. Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4g/0.5g administered to critically ill patients with severe nosocomial pneumonia. Intensive Care Med 2004; 30: 976–9PubMedCrossRef

111.

Laethem T, De Lepeleire I, McCrea J, et al. Tissue penetration by ertapenem, a parenteral carbapenem administered once daily, in suction-induced skin blister fluid in healthy young volunteers. Antimicrob Agents Chem 2003 Apr; 47(4): 1439–42CrossRef

112.

Burkhardt O, Majacher-Peszynska J, Borner K, et al. Penetration of ertapenem into different pulmonary compartments of patients undergoing lung surgery. J Clin Pharmacol 2005; 45: 659–65PubMedCrossRef

113.

Tomaselli F, Maier A, Matzi V, et al. Penetration of meropenem into pneumonic human lung tissue as measured by in vivo microdialysis. Antimicrob Agents Chem 2004 Jun; 48(6): 2228–32CrossRef

114.

Tegeder I, Schmidtko A, Brautigam L, et al. Tissue distribution of imipenem in critically ill patients. Clin Pharmacol Ther 2002; 71: 325–33PubMedCrossRef

115.

Rana B, Butcher I, Grigoris P, et al. Linezolid penetration into osteo-articular tissues. J Antimicrob Chem 2002; 50: 747–50CrossRef

116.

Honeybourne D, Tobin C, Jevons G, et al. Intrapulmonary penetration of linezolid. J Antimicrob Chem 2003; 51: 1431–4CrossRef

Title: Use of Pharmacodynamic Principles to Optimise Dosage Regimens for Antibacterial Agents in the Elderly
Authors: Ayman M. Noreddin
Virginia Haynes
Publication date: 01-04-2007
Publisher: Springer International Publishing
Published in: Drugs & Aging / Issue 4/2007
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI: https://doi.org/10.2165/00002512-200724040-00002

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2007

Pharmacotherapy for Nocturia in the Elderly Patient

Management of Acute Exacerbations of Chronic Obstructive Pulmonary Disease in the Elderly

When Should Levodopa Therapy be Initiated in Patients with Parkinson’s Disease?

Onychomycosis in the Elderly

Does Glycoprotein IIIa Gene(PlA) Polymorphism Influence Clopidogrel Resistance?

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials